Patients with heart failure (HF) and reduced ejection fraction (HFrEF) in Asia exhibit many differences from those in other parts of the world. The purpose of this case is to investigate the efficacy and safety of dapagliflozin, compared with placebo, in HFrEF patients in Asia, compared to those elsewhere, enrolled in the DAPA-HF trial.JACC: Asia Editor-in-Chief Jian’an Wang, MD, PhD, FACCCME Editor Kenneth A. Ellenbogen, MD
AuthorsKieran F. Docherty, MB ChBJohn J.V. McMurray, MD
Important Dates
Date of Release: April 19, 2022Term of Approval/Date of CME/MOC/ECME Expiration: April 18, 2023